Entera Bio Ltd. (NASDAQ: ENTX) announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral PTH(1-34) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE